Fulcrum Therapeutics, Inc. (FULC) Form 8-K — Aug 10, 2026

$FULCForm 8-KItems 5.02Filed Aug 10, 2026, 8:43 AM ET0001193125-26-341385Original filing

Fulcrum Therapeutics confirmed that Greg Tourangeau, its Vice President of Finance and principal accounting officer, ended his tenure on August 7, 2026. The departure was mutually agreed and had been previously disclosed in a Form 8-K filed June 11, 2026. In response, Fulcrum's board appointed Alan Musso, the company's chief financial officer and principal financial officer, as principal accounting officer effective August 7, 2026. Musso will receive no additional compensation for taking on the role.

Price after filing

1 day: -1.6%7 days: +2.4%30 days: +1.9%

Close on the filing date to close N calendar days later (from $3.75). Historical, not a forecast.

AI analysis

Red flags1 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.